Palisade Bio (PALI) Cash from Operations (2010 - 2026)
Palisade Bio (PALI) posted quarterly Cash from Operations of 3890000.0 for Q1 2026, down 66.74% year-over-year from 11695064.43 in Q1 2025, and down 23.73% quarter-over-quarter from 3144000.0 in Q4 2025.
Powered by 
Analysis
Palisade Bio (PALI) Cash from Operations (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Cash from Operations for 17 consecutive years, with 3890000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 66.74% year-over-year to 3890000.0; the TTM figure through Mar 2026 stood at 12404000.0 (down 9.32% YoY), while the FY2025 annual figure was 10847000.0, up 11.04% from the prior year.
- Cash from Operations declined to 3890000.0 in Q1 2026 per PALI's latest filing, from 3144000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 1817000.0 in Q2 2025 and bottomed at 3890000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 3024882.35 across 5 years, with a median of 3144000.0 in 2025.
- On a YoY basis, Cash from Operations climbed as much as 57.91% in 2022 and fell as far as 201.12% in 2022.
- Palisade Bio's Cash from Operations stood at 3306000.0 in 2022, then grew by 16.94% to 2746000.0 in 2023, then increased by 13.29% to 2381000.0 in 2024, then tumbled by 32.05% to 3144000.0 in 2025, then dropped by 23.73% to 3890000.0 in 2026.
- Business Quant data shows PALI's Cash from Operations at 3890000.0 in Q1 2026, 3144000.0 in Q4 2025, and 3553000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - | -7.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.60 Mn |
| Mar 31, 2026 | -3.89 Mn |
| Dec 31, 2025 | -3.14 Mn |
| Sep 30, 2025 | -3.55 Mn |
| Jun 30, 2025 | -1.82 Mn |
| Mar 31, 2025 | -2.33 Mn |
| Dec 31, 2024 | -2.38 Mn |
| Sep 30, 2024 | -3.13 Mn |
| Jun 30, 2024 | -3.50 Mn |
| Mar 31, 2024 | -3.18 Mn |
| Dec 31, 2023 | -2.75 Mn |
| Sep 30, 2023 | -2.66 Mn |
| Jun 30, 2023 | -2.20 Mn |
| Mar 31, 2023 | -3.53 Mn |
| Dec 31, 2022 | -3.31 Mn |
| Sep 30, 2022 | -3.04 Mn |
| Jun 30, 2022 | -3.25 Mn |
| Mar 31, 2022 | -3.76 Mn |
| Dec 31, 2021 | -3.06 Mn |
| Sep 30, 2021 | -2.75 Mn |